871 related articles for article (PubMed ID: 26515757)
1. Treatment of rheumatoid arthritis: Unraveling the conundrum.
Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
[TBL] [Abstract][Full Text] [Related]
2. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
Levesque MC
BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
[TBL] [Abstract][Full Text] [Related]
3. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
4. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
Yen JH
Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
[TBL] [Abstract][Full Text] [Related]
5. Use of biologics in rheumatoid arthritis: where are we going?
Pucino F; Harbus PT; Goldbach-Mansky R
Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S19-41. PubMed ID: 16960244
[TBL] [Abstract][Full Text] [Related]
6. The use of biologic therapies in the treatment of rheumatoid arthritis.
Wang D; Li Y; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis and the era of biologic therapy.
Malaviya AP; Ostör AJ
Inflammopharmacology; 2012 Apr; 20(2):59-69. PubMed ID: 22366810
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
9. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
10. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
11. Biological therapies for rheumatoid arthritis: progress to date.
Malviya G; Salemi S; Laganà B; Diamanti AP; D'Amelio R; Signore A
BioDrugs; 2013 Aug; 27(4):329-45. PubMed ID: 23558378
[TBL] [Abstract][Full Text] [Related]
12. Strategies toward rheumatoid arthritis therapy; the old and the new.
Abbasi M; Mousavi MJ; Jamalzehi S; Alimohammadi R; Bezvan MH; Mohammadi H; Aslani S
J Cell Physiol; 2019 Jul; 234(7):10018-10031. PubMed ID: 30536757
[TBL] [Abstract][Full Text] [Related]
13. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
14. Unmet needs in rheumatoid arthritis.
Moreland L
Arthritis Res Ther; 2005; 7 Suppl 3(Suppl 3):S2-8. PubMed ID: 15960819
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression.
Hosoya T; Iwai H; Yamaguchi Y; Kawahata K; Miyasaka N; Kohsaka H
Ann Rheum Dis; 2016 Jan; 75(1):253-9. PubMed ID: 25165034
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
[TBL] [Abstract][Full Text] [Related]
17. Impact of rheumatoid arthritis in Turkey: a questionnaire study.
Direskeneli H; Akkoç N; Bes C; Cakir N; Cefle A; Cobankara V; Dalkilic E; Dinc A; Ertenli I; Gul A; Hamuryudan V; Inanc M; Kalyoncu U; Karaaslan Y; Kasifoglu T; Keser G; Keskin G; Kisacik B; Kiraz S; Masatlioglu S; Onat AM; Ozbek S; Ozturk MA; Pamuk ON; Pay S; Pirildar T; Sayarlioglu M; Senel S; Senturk T; Tasan D; Terzioglu E; Yazici A; Yucel E
Clin Exp Rheumatol; 2014; 32(4):477-83. PubMed ID: 24960289
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
19. Rheumatoid arthritis: treating to target with disease-modifying drugs.
Firth J
Br J Nurs; 2011 Oct 28-Nov 9; 20(19):1240, 1242, 1244-5. PubMed ID: 22067836
[TBL] [Abstract][Full Text] [Related]
20. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.
Brezinschek HP; Brickmann K; Yazdani-Biuki B; Dörner T; Graninger WB; Brezinschek RI
Wien Med Wochenschr; 2006 Jan; 156(1-2):61-7. PubMed ID: 16465615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
